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ABSTRACT: 
Aim: To examine if fasting affects serum bilirubin levels in clinical healthy males and females. 
 
Methods: We utilised retrospective data from phase 1 clinical trials where blood was collected in 
either a fed or fasting state at screening and pre-dosing time points and analysed for total bilirubin 
levels as per standard clinical procedures.  Participants were clinically healthy males (n = 105) or 
females (n = 30) aged 18 to 48 inclusive who participated in a phase 1 clinical trial in 2012 or 2013.    
 
Results: We found a statistically significant increase in total serum bilirubin levels in fasting males as 
compared to non-fasting males.  The fasting time correlated positively with increased bilirubin levels.  
The age of the healthy males did not correlate with their fasting bilirubin level.  We found no 
correlation between fasting and bilirubin levels in clinically normal females.   
 
Conclusions:  The recruitment and screening of volunteers for a clinical trial is a time-consuming and 
expensive process.  This study clearly demonstrates that testing for serum bilirubin should be 
conducted on non-fasting male subjects.  If fasting is required, then participants should not be 
excluded from a trial based on an elevated serum bilirubin that is deemed non-clinically significant.  
 
WHAT THIS PAPER ADDS: 
This paper provides evidence that serum bilirubin levels increase in clinically normal males after 
fasting for over 12 hours.  This should be taking into consideration when designing the protocol for 
clinical trials such that an elevated bilirubin measure from a fasted male may not be cause for 
exclusion when all other liver function tests are clinically normal.   
 
 
INTRODUCTION: 
A phase 1 clinical trial often requires the recruitment of clinically normal males and females or 
‘healthy volunteers’.  Phase 1 clinical trials have very strict inclusion/exclusion criteria which can 
make the recruitment of appropriate subjects time-consuming and costly.  The biochemical 
parameters for inclusion must be within a pre-defined range as documented in the clinical trial 
protocol.  Often a single biochemical parameter that is detected outside of the pre-defined range is 
sufficient for exclusion of a willing participant from a trial.  Very often this single abnormal 
biochemical parameter which excludes the participant is not considered clinically significant by a 
medical practitioner. 
Recently, we have experienced several cases where a willing participant is excluded from a trial due 
to elevated bilirubin levels (non-clinically significant) detected at either screening or the pre-dose 
biochemical testing.  These levels fall outside of the pre-determined range as set by the clinical trial 
protocol and thus the subject is excluded despite the levels not being considered clinically 
significant.  Even more frustrating for the willing participant is the fact that often a single 
biochemical parameter, in this case elevated bilirubin is outside of the inclusion/exclusion criteria.  
This can lead to frustration for the willing participant and for the contract research organisation. 
 
Commonly participants are required to fast prior to blood collection for the medical screening.  
Additionally for some studies, participants fast overnight in the clinic before baseline blood 
collection immediately preceding dosing with the study drug.  We hypothesise that this fasting is 
increasing the levels of serum bilirubin in otherwise clinically normal participants and thus excluding 
willing volunteers with normal non-fasting bilirubin levels.  To investigate this hypothesis, we have 
retrospectively examined the fed and fasting serum bilirubin levels of clinically normal males and 
females who participated in a phase 1 clinical trial. 
 
 
MATERIALS AND METHODS: 
Study site: 
Q-Pharm Pty Limited is a specialised contract research organisation located at the Royal Brisbane 
and Women’s Hospital campus at Herston in Brisbane, Queensland, Australia which undertakes a 
broad range of predominantly early phase clinical trials for clients in the global pharmaceutical and 
biotechnology industries.  
 
Study population: 
All participants were clinically healthy males (n = 105) or females (n = 30) aged 18 to 48 inclusive 
who participated in a phase 1 clinical trial in 2012 or 2013.   All participants successfully passed the 
medical screening (ie: biochemistry and haematology were within the clinically normal range) for 
their particular study and all were successfully dosed with the study drug.  All participants had a 
thorough medical history recorded including no previous episodes of jaundice or any family history 
of liver disease.  All trials were phase 1 trials examining the safety and tolerability of novel drugs 
and/or drug formulations.  All participants contributed two blood samples to this study – a screening 
sample and a base-line (pre-dose) sample.   
 
Ethics: 
All phase 1 clinical trials from which we retrospectively obtained the bilirubin measurements were 
approved by either the QIMR Berghofer – Human Research Ethics Committee or the Bellberry 
Human Research Ethics Committee.  All trials were conducted in accordance with the ICH GCP 
guidelines and the National Statement on Ethical Conduct in Human Research (2007) as produced by 
the National Health and Medical Research Council of Australia.  
 
Classification of bilirubin measurements as fed or fasting: 
The source notes for phase 1 studies document the time at which the participant last consumed a 
meal.  Therefore, we were able to determine the exact period of fasting prior to blood collection.  
Fasting as described in the trial source notes is no food or drink except water.  For those blood 
samples obtained for medical screening – these fasting times are self-reported.  For those blood 
samples obtained for baseline measurements (ie: prior to dosing) this fasting is usually during 
overnight confinement in the study clinic.  The majority of fed measurements were done at 
screening and the majority of fasting measurements were performed at baseline after an overnight 
fast (~12hours) in the study clinic.  Therefore, the accuracy of the reported fasting times is well 
assured.  The period of time subjects were fasted prior to collection of all bilirubin measurements 
was calculated and graphed to enable classification into fasting and non-fasting (Figure 1). 
 
Participant bilirubin measurements were classified as fed if less than 6 hours had passed since 
consumption of food prior to the blood being collected.  Participants were classified as fasting if no 
food other than water had been consumed for 10-20 hours prior to the blood being collected.  We 
have excluded those fasting times that were between 6 and 10 hours to better differentiate 
between the fed and fasting cohorts.  We also removed the outlier of 21 hours from further analysis 
due to the extreme length of this fasting period and its likely effect on clinical measurements.   
 
Blood collection and processing for bilirubin measurements: 
The blood collection time-points analysed herein were performed at two stages of the trial process;   
i) medical screening and ii) baseline blood collection prior to administration of the study drug.  No 
blood collection performed after the administration of study drug was analysed as part of this study 
and all participants were classified as being clinically healthy and continued onto their particular trial 
and study drug dosing.  All blood was sent to licensed pathology laboratories in Brisbane, 
Queensland, Australia and was tested for serum bilirubin on either a DXC800 (Beckman Coulter, 
U.S.A) or Abbott Architect c16000 (Abbott diagnostics, Abbott Park, Illinois, U.S.A) platform as per 
standard clinical testing procedures. 
 
Classification of the normal range for bilirubin serum measurements: 
The normal serum Bilirubin range for this study was as utilised by Sullivan and Nicolaides Pathology 
for their biochemical measurements.  For females the lower limit of normal (F-LLN) was 3umol/L and 
the upper limit of normal (F-ULN) was 15umol/L.  For males the lower limit of normal (M-LLN) was 
4umol/L and the upper limit of normal (M-ULN) was 20umol/L.   
 
Demographics of phase 1 trial participants analysed in this study: 
All clinical trial participants self-assigned to one of four races during screening; Caucasian, Asian, 
Aboriginal/Torres Strait Islander or other.  Participants also self-identify as being of Hispanic or 
Latino descent.  In the five clinical trials examined for this study, approximately 85% of the 
participants identified as being Caucasian.  The average age of the trial participants was 25.4 years 
(±0.44 SEM).  The youngest trial participant was 18 years of age and the oldest was 48 years of age.   
The 25th to 75th percentile ranged from 22 to 27 years (Figure 2). 
 
Statistical analysis: 
The datasets were analysed using GraphPad Prism version 6.00 for Windows (GraphPad Software, La 
Jolla California, USA).  Box and whiskers graphs were utilised with the mean, median, 25th and 75th 
percentile calculated for each dataset.  We utilised the D'Agostino & Pearson omnibus normality test 
to test each cohort for Gaussian distribution.  We utilised an unpaired t-test to examine the 
significance of bilirubin levels between fed and fasting cohorts of males (Mann Whitney) and 
females (Welch’s correction).  We also utilised Linear Regression to examine the relationship 
between serum bilirubin levels and the age and fasting time of the male participants. 
 
 
RESULTS: 
Serum bilirubin levels: 
Fed males:  Blood was collected from 97 clinically normal ‘fed’ male phase 1 trial participants at 
screening or pre-dose blood collection and analysed for total serum bilirubin (Table 1).  The mean 
serum bilirubin measurement for this cohort was 10.42umol/L (±0.4SEM).  The 25th to 75th percentile 
ranged from 7umol/L to 12umol/L.  The serum bilirubin levels for this cohort were not normally 
distributed.  The lowest measurement was 5umol/L and the highest reading was 21umol/L.  Two 
patients (out of 97) or 2% had a serum bilirubin above the ULN; both recorded 21umol/L. 
  
Bilirubin (umol/L) Fed Males Fasted Males Fed Females Fasted Females 
- n = 97 n = 109 n = 25 n = 33 
Minimum  5 7 2 4 
25% Percentile 7 11 5 6 
Median 10 14 8 9 
75% Percentile 12 18.5 11.5 12 
Maximum  21 35 18 18 
10% Percentile 6 8 4 5 
90% Percentile 16 22 14 16.2 
Mean  10.42 14.85 8.4 9.636 
Std. Deviation 3.856 5.744 3.905 3.904 
Std. Error of Mean 0.3916 0.5502 0.781 0.6795 
Lower 95% CI of mean 9.645 13.76 6.788 8.252 
Upper 95% CI of mean 11.2 15.94 10.01 11.02 
 
Table 1. Serum bilirubin measurements.  Descriptive statistics for the male and female fed and 
fasted cohorts.  Data shown includes the 25th to 75th percentile for each cohort, the mean, minimum 
and maximum measurements. 
 
Fasted males:  Blood was collected from 109 clinically normal ‘fasted’ male phase 1 trial participants 
at screening or pre-dose blood collection and analysed for total serum bilirubin (Table 1).  The mean 
serum bilirubin measurement for this cohort was 14.85umol/L (±0.55SEM).  The 25th to 75th 
percentile ranged from 11.0umol/L to 18.5umol/L.  The serum bilirubin levels for this cohort were 
not normally distributed.  The lowest measurement was 7umol/L and the highest reading was 
35umol/L. Fifteen patients (out of 109) or 13.76% recorded bilirubin measurements above the ULN.  
These were 21umol/L (x2), 22 umol/L (x5), 24umol/L, 25umol/L (x2), 27umol/L, 28umol/L, 31umol/L, 
33umol/L and 35umol/L.  
 
Fed females:  Blood was collected from 25 clinically normal ‘fed’ female phase 1 trial participants at 
screening or pre-dose blood collection and analysed for total serum bilirubin (Table 1).  The mean 
serum bilirubin measurement for this cohort was 8.4umol/L (±0.78 SEM).  The 25th to 75th percentile 
ranged from 5.0umol/L to 11.5umol/L.  The serum bilirubin levels for this cohort were normally 
distributed.  The lowest measurement was 2.0umol/L and the highest reading was 18.0umol/L.  One 
patient (out of 25) or 4% had a serum bilirubin above the ULN; 18umol/L. 
 
Fasted females:  Blood was collected from 33 clinically normal ‘fed’ female phase 1 trial participants 
at screening or pre-dose blood collection and analysed for total serum bilirubin (Table 1).  The mean 
serum bilirubin measurement for this cohort was 9.63umol/L (±0.68 SEM).  The 25th to 75th 
percentile ranged from 6.0umol/L to 12.0umol/L.  The serum bilirubin levels for this cohort were 
normally distributed.  The lowest measurement was 4.0umol/L and the highest reading was 
18.0umol/L.  Three patients (out of 33) or 9% had a serum bilirubin above the ULN; 17umol/L and 2 x 
18umol/L. 
 
Comparison of serum bilirubin levels between fed and fasted cohorts: 
To determine if fasting effected serum bilirubin levels the statistical analysis programs in the 
GraphPad Prism software were utilised; all data points including those above the ULN were included 
in the analysis.  Significant differences between the serum bilirubin levels in the male fed and fasted 
cohorts (Figure 3) were found (p < 0.0001).  Conversely no significant difference in the serum 
bilirubin levels between the female fed and fasted cohorts were identified. Fasting increased the 
mean serum bilirubin levels by 4.4umol/L in males compared to 1.2umol/L in females. 
 
Fasting time increases serum bilirubin levels in clinically normal males: 
To further examine the effect of fasting on male bilirubin levels we plotted the fasting times in direct 
comparison to the serum bilirubin levels.  We then performed a linear regression and found a 
positive correlation between bilirubin levels and increased fasting time (Figure 4).  The slope of the 
line was 0.4313 ± 0.06733.   The equation of the line was (Y = 0.4313*X + 9.227) where Y is serum 
bilirubin levels and X is the hours fasted. 
 
Age does not influence fasting bilirubin levels in clinically normal males: 
To examine the effect of age on male bilirubin levels we plotted the age in direct comparison to the 
serum bilirubin levels.  We then performed a linear regression and found no correlation between 
bilirubin levels and participant age (Figure 5).  The slope of the line was 0.09419 ± 0.1303.  The 
equation of the line was (Y = 0.09419*X + 12.61) where Y is serum bilirubin levels and X is the age of 
the participant. 
 
DISCUSSION: 
This retrospective study demonstrates a statistically significant relationship between fasting and 
elevated bilirubin in otherwise healthy male subjects enrolled in phase 1 clinical trials.  These results 
are consistent with previous studies including the South African study reported by Meyer and 
colleagues in 1995, albeit from a much smaller sample size, where they reported a rise in serum 
bilirubin levels in healthy males following fasting (1).  
 
Several other studies have examined total bilirubin levels after an overnight fast.  These ‘fasting’ 
total bilirubin levels were found to decrease following consumption of breakfast (2) and/or lunch (3).  
These studies, whilst in agreement with ours did not separate the male and female populations and 
were conducted on relatively small cohorts of 17 (9 males and 8 females)(2) and 20 (10 males and 10 
females)(3) subjects respectively.  We included females (25 fed and 33 fasted) in our retrospective 
study and found that fasting had no significant effect on serum bilirubin levels in clinically normal, 
healthy females.   
 
The mechanism underlying the cause of hyperbilirubinaemia in fasted healthy males remains 
undetermined.  Further investigation of additional confounding biochemical analytes and their 
response to fasting is required.  We found no correlation between age and fasted bilirubin levels. 
   
A recent review paper on clinical tests of liver metabolism by Woreta states that fasting and stress 
increase bilirubin(4).  A study by Lopardo and colleagues in 2013 showed that fasting increases 
serum concentrations of Bilirubin in patients receiving Atazanavir therapy for HIV(5).  However, it 
should be noted that food affects atazanavir levels and the drug itself causes hyperbilirubinaemia(5).    
Lopardo proposes that an increased hepatic uptake of nonesterified fatty acids interferes with the 
hepatic clearance of bilirubin and thus contributes to the unconjugated hyperbilirubinemia of 
fasting(5).  Similar mechanisms may be at work in healthy males. 
 
Alternative causes of isolated elevations in bilirubin were explored. Laboratory artefact including in 
vitro haemolysis was excluded by adherence at all times to the recommended specimen handling 
and transport recommendations in addition to the inclusion of a “haemolysis index” with each 
episode of analysis which was reported as normal.  Laboratory QA/QC data was reviewed and found 
to be within acceptable limits to ensure accuracy of the reported results and as such that there was 
no laboratory error to account for the reported abnormalities.  In addition total bilirubin has been 
shown to be suitable for clinical analysis after 24 hours of storage at 4°C and RT in an assortment of 
storage tubes(6).    
 
The most common inherited disorder of bilirubin metabolism is Gilbert syndrome which is typically 
regarded as a benign condition characterised by recurrent episodes of jaundice occasionally 
triggered by a number of insults including intercurrent disease, overexertion, dehydration, 
menstruation and fasting (7).  Gilbert syndrome is the result of a defect in the promotor of the gene 
that encodes the enzyme uridine diphosphoglucuronate-glucuronosyltransferase 1A1 (UGT1A1), 
which is responsible for the conjugation of bilirubin with glucuronic acid.  
 
The hyperbilirubinemia in patients with Gilbert syndrome is unconjugated.  The current local 
prevalence of Gilbert syndrome is difficult to estimate however in different populations it has been 
reported to range between 4 and 16 percent (8-16) which is not sufficient to explain the results 
found in this study.  The prevalence is higher in males, possibly due to a relatively higher level of 
daily bilirubin production (17).  The next step in this research would be to test all those who show 
elevated fasted bilirubin for Gilberts disease as definitive proof of the true incidence of Gilbert’s in 
the local clinical normal population.                   
 
The primary limitation of this study was that it was restrospective analysis of data collected from a 
number of different phase 1 clinical trials.  Given that the time-points analysed were all prior to the 
receipt of any investigational product or trial drug, the subject’s participation in a clinical trial has 
not impacted on the results presented.   
 
The strengths of this study include the accuracy of the documentation of the time the subjects were 
fasting as the majority were confined for the purpose of the clinical trial and thus being closely 
observed.  Obviously self-reporting of fasting is likely to be far less accurate.  Further the volume of 
clinical trials conducted at our facility has permitted the analysis of a large sample size to reduce the 
impact of any confounders.  Further given the importance of accuracy in clinical trials strict attention 
was paid to standard operating procedures outlining the collection, handling and transport of 
pathology specimens to ensure consistency and accuracy of pathology results. 
 
Given all subjects analysed in this study were by definition healthy volunteers who had to have no 
significant medical history and a normal thorough clinical examination the probability of intercurrent 
illness and concomitant medications impacting on these results is extremely low.  Although there 
has been some reporting of this association in the literature in the past (1) this is by far the largest 
study of this type reported to date. 
 
This study demonstrates a statistically significant association between elevated bilirubin and fasting 
in males.  Furthermore, we have determined that this is unaffected by the age of the participant and 
that the length of fasting directly affects the serum bilirubin levels.  These findings are important for 
many reasons.  Healthy volunteers for clinical trials are a precious resource and so when excluded on 
the basis of a (not clinically significant) abnormal pathology result a significant amount of time, 
effort and money is lost not to mention the impact on the conduct of the trial. Proving an 
association between fasting and hyperbilirubinaemia can result in the more accurate interpretation 
of non clinically significant abnormal bilirubin results and provide evidence for limiting the period of 
fasting prior to blood collection unless fasting is absolutely necessary.  This work has the potential to 
improve the recruitability of healthy volunteer clinical trials in addition to reducing unnecessary 
repetition of pathology results which can add significant expense. 
 
 
TAKE HOME MESSAGES: 
-   Fasting increases total serum bilirubin levels in clinically normal males but not females. 
- We utilised retrospective data from fed and fasting clinically normal participants in phase 1 clinical 
trials (screening and pre-dose blood only) thus it is highly unlikely that other confounding diseases 
contributed to the elevated bilirubin levels. 
- A fasting bilirubin measure that is considered non-clinically significant by a clinician should thus not 
be used as clinical trial exclusion criteria if the remainder of the liver function tests are normal. 
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